Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 1 |
2019 | 1 |
2020 | 1 |
2022 | 2 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
N Engl J Med. 2020.
PMID: 32101663
Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators.
Modi S, et al.
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
N Engl J Med. 2022.
PMID: 35665782
Free PMC article.
Clinical Trial.
Item in Clipboard
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators.
Schmid P, et al.
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
N Engl J Med. 2022.
PMID: 35139274
Clinical Trial.
Item in Clipboard
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators.
Martín M, et al.
J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500. Online ahead of print.
J Clin Oncol. 2024.
PMID: 38537155
Item in Clipboard
[Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV, Zavalishina LE, Ganshina IP, Andreeva YY, Frank GA, Gordeeva OO, Zhukova LG, Meshcheryakov AA, Savelov NA, Tuzova EA, Morozov DA, Poddubnaya IV.
Kolyadina IV, et al. Among authors: ganshina ip.
Arkh Patol. 2019;81(6):56-62. doi: 10.17116/patol20198106156.
Arkh Patol. 2019.
PMID: 31851193
Russian.
Item in Clipboard
Variations in the number of regulatory T cells (CD4+CD25+) in patients with breast cancer during herceptin therapy.
Slavina EG, Chertkova AI, Zabotina TN, Gan'shina IP, Lichinitser MR.
Slavina EG, et al.
Bull Exp Biol Med. 2006 Mar;141(3):361-3. doi: 10.1007/s10517-006-0171-7.
Bull Exp Biol Med. 2006.
PMID: 17073160
Clinical Trial.
Item in Clipboard
Cite
Cite